This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Although an immunochemical test for prostate specific antigen (PSA) test has proved valuable for early diagnosis of prostate adenocarcinoma (PCa), elevated PSA levels are also seen in a number of other prostatic conditions that have distinct therapeutic requirements, such as benign prostate hyperplasia (BPH). Biomarkers other than PSA that can be assessed in biopsy specimens, in serum or in urine will be valuable in determining the appropriate strategy for intervention. Monoclonal antibodies (MAbs) provide a rapid and specific means of detecting the presence of biomarkers, independent of whether they result from changes in gene and protein expression, or from biological modification of proteins or other macromolecules. We propose to isolate antibodies that recognize novel biomarkers associated with tumorigenic potential of prostate cells. The underlying hypothesis of this work is that detectable antigens are differentially expressed in prostate cells as they become oncogenically transformed. Identification of these antigens, some of which are likely to be present on the surfaces of cells, may be performed using paired cell lines that differ in tumorigenic potential. Although MAbs can be easily used to distinguish antigens on cells, isolation of MAbs by traditional, hybridoma methods is difficult in the absence of purified antigen. Antibody phage display permits the use of affinity subtraction and purification techniques for selection of MAbs (Aim 1) binding to antigens that differ between closely related cell types, even without prior knowledge of the nature of the antigens involved. Lineage-related human prostate cell lines, RWPE-1 and RWPE-2, which differ in the absence/presence of a Ki-Ras gene, are an ideal platform for identification of tumorigenicity-associated antigens. Antibody phage display libraries will be subtracted on RWPE-1 and selected on RWPE-2 cell lines. MAbs identified in this manner will be verified for their specificity (Aim 3) for tumorigenic cultured cells, and their cognate antigens characterized (Aim 2). Archived serum, radical prostatectomy and biopsy specimens from localized and metastatic PCa will be probed with the novel MAbs to determine the scope of expression of the antigens in cancer patients. The primary outcome of this study will be novel antibodies against biomarkers associated with tumorigenic prostate disease. This will have an impact on diagnosis and treatment of prostatic cancer in that they will permit the development of diagnostic assays that can predict the tumorous potential of abnormal prostatic growth. Antibodies or other molecules directed against these antigens may also prove novel therapeutic targets and thus have the potential to dramatically reduce mortality.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12RR003062-20
Application #
7336080
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-06-01
Project End
2007-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
20
Fiscal Year
2006
Total Cost
$119,094
Indirect Cost
Name
Clark Atlanta University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
065325177
City
Atlanta
State
GA
Country
United States
Zip Code
30314
Morton, Derrick J; Patel, Divya; Joshi, Jugal et al. (2017) ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation. Oncotarget 8:2536-2549
Joshi, Jugal Bharat; Patel, Divya; Morton, Derrick J et al. (2017) Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52. Mol Oncol 11:337-357
Komaragiri, Shravan Kumar; Bostanthirige, Dhanushka H; Morton, Derrick J et al. (2016) ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells. Biochem Biophys Res Commun 478:60-66
Wilder, Catera L; Walton, Charlene; Watson, Valencia et al. (2016) Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells. Int J Biochem Cell Biol 79:199-208
Burton, Liza J; Smith, Basil A; Smith, Bethany N et al. (2015) Muscadine grape skin extract can antagonize Snail-cathepsin L-mediated invasion, migration and osteoclastogenesis in prostate and breast cancer cells. Carcinogenesis 36:1019-27
Goodson 3rd, William H; Lowe, Leroy; Carpenter, David O et al. (2015) Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis 36 Suppl 1:S254-96
Brown, Shanora G; Knowell, Ashley E; Hunt, Aisha et al. (2015) Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis. Prostate 75:266-79
Muniyan, Sakthivel; Chou, Yu-Wei; Tsai, Te-Jung et al. (2015) p66Shc longevity protein regulates the proliferation of human ovarian cancer cells. Mol Carcinog 54:618-31
Chinaranagari, Swathi; Sharma, Pankaj; Bowen, Nathan J et al. (2015) Prostate cancer epigenome. Methods Mol Biol 1238:125-40
Mandal, S; Abebe, F; Chaudhary, J (2014) -174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race. Genet Mol Res 13:139-51

Showing the most recent 10 out of 99 publications